Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc. (PTHS): 7 pipeline candidates · 4 upcoming catalysts · ~10 mo cash runway. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
9.9 months
D/E 3.14 · 0% dilution
Lead: Approved
7 candidates
4 upcoming, next in ~1542d
0 buys · 9 sells (180d)
A transparent, data-derived signal for Pelthos Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$92.1M
Cash
$32.0M
Quarterly Burn
$13.1M
Runway
9.9 mo
Revenue
$10.9M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (7 candidates)
Upcoming Catalysts (4)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
14
Total value held
$9.2M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 186,186 | $3.9M |
| boothbay fund management, llc | 81,858 | $1.7M |
| j. goldman & co lp | 50,415 | $1.1M |
| cantor fitzgerald, l. p. | 41,423 | $870K |
| diadema partners lp | 24,773 | $520K |
| knott david m jr | 21,073 | $443K |
| geode capital management, llc | 15,290 | $321K |
| vanguard fiduciary trust co | 9,817 | $206K |
| persistent asset partners ltd | 6,007 | $126K |
| steward partners investment advisory, llc | 1,910 | $40K |
Showing top 10 of 14 institutional holders of Pelthos Therapeutics Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Pelthos Therapeutics Inc.'s pipeline?
Pelthos Therapeutics Inc. (PTHS) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Pelthos Therapeutics Inc.'s lead drug candidate?
Pelthos Therapeutics Inc.'s most advanced tracked candidate is cc8464 (Phase 1) for Neuropathic pain, specifically Erythromelalgia (EM) and idiopathic small fiber neuropathy (iSFN).
What is Pelthos Therapeutics Inc.'s next catalyst?
Pelthos Therapeutics Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: SILENOR" — expected September 7, 2030.
What is Pelthos Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Pelthos Therapeutics Inc. has approximately 9.9 months of cash runway.
What is Pelthos Therapeutics Inc.'s market capitalization?
Pelthos Therapeutics Inc.'s market capitalization is approximately $92.1M.
Get the full picture on Pelthos Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.